stockrow
Friday 6 November 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
0.94
0.04
+4.44%
Follow GUTS
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — |
Altman Z-Score |
— | (6.98) | — | — |
P/S ratio |
— | 964.08 | 225.02 | — |
Altman Z″-Score (non-manufacturers) |
— | (14.81) | (18.05) | — |
P/FCF ratio |
— | 0.00 | 0.00 | — |
P/Operating CF |
— | (5.26) | (2.55) | — |
P/B ratio |
— | 3.15 | 0.00 | — |
Price to Tangible BV |
— | 3.15 | 0.00 | — |
EV/Sales |
— | 562.98 | 405.25 | — |
EV/EBITDA |
— | 0.00 | 0.00 | — |
EV/Operating CF |
— | (0.80) | (1.14) | — |
EV/FCF |
— | (0.78) | (1.13) | — |
Quick Ratio |
4.45 | 3.41 | 3.00 | 6.74 |
Current Ratio |
4.78 | 3.63 | 3.19 | 7.06 |
Net Debt/EBITDA |
0.53 | 0.40 | (0.43) | 0.64 |
Debt/Assets |
25.19% | 27.91% | 72.37% | 29.14% |
Debt/Equity |
3.23 | 1.06 | (0.17) | (0.07) |
Asset Turnover |
0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.64 | 0.95 | 0.45 | 0.73 |
Capex/Depreciation |
(0.49) | (2.61) | (1.26) | (0.12) |
| (744.17%) | 46.32% | 32.65% | 0.00% | |
| (122.85%) | (74.55%) | (137.45%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(196.71%) | (124.97%) | (377.84%) | (142.53%) |
Average Days of Receivables |
— | 0.00 | 66.92 | — |
Research and Development Expense of Revenue |
0.00% | 75,775.27% | 31,698.33% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 24,841.94% | 10,700.83% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 15,511.83% | 3,580.00% | 0.00% |
Graham Net Nets |
— | (0.09) | (13.54) | — |
Graham Number |
— | 0.00 | 4,426.56 | — |
Earnings Yield |
— | (74.30%) | (304.20%) | — |
Free Cash Flow Yield |
— | (75.05%) | (159.92%) | — |
Revenue per Share |
0.00 | 0.03 | 0.69 | 0.00 |
Operating CF per Share |
(14.30) | (18.06) | (247.10) | (278.91) |
Capex per Share |
(0.09) | (0.49) | (2.07) | (0.34) |
Free Cash Flow per Share |
(14.39) | (18.55) | (249.17) | (279.25) |
Cash per Share |
12.91 | 18.60 | 193.44 | 297.16 |
Shareholders Equity per Share |
1.50 | 7.84 | (1,875.72) | (1,521.83) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.50 | 7.84 | (1,875.72) | (1,521.83) |
Free Cash Flow |
(90.88) | (67.29) | (43.18) | (46.30) |
Working Capital |
69.25 | 51.99 | 24.46 | 44.32 |
Capital Expenditures |
(0.56) | (1.76) | (0.36) | (0.06) |
Net Current Asset Value |
(24.37) | (7.89) | (365.63) | (261.65) |
EV/EBIT |
— | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 18.98 | 2.99 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.47 | 0.23 | 0.58 | 1.39 |
Cash ROIC |
(74.75%) | (53.38%) | 18.27% | 24.99% |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.03 | 0.10 | — |
Inventory Turnover |
— | 0.68 | 0.00 | — |
Average Days of Payables |
0.00 | 23,652.00 | 2,621.36 | 0.00 |
Days of Inventory on Hand |
— | 532.90 | 346.04 | — |
Average Payables |
2.41 | 1.90 | 0.77 | — |
Average Inventory |
— | 0.07 | — | — |
Average Assets |
114.74 | 92.14 | 68.58 | — |
Average Common Equity |
18.94 | (148.32) | (288.69) | — |
Columns are period end dates · fundamentals updated 2 Nov 2026